Claritin for OTC allergy relief
This article was originally published in The Tan Sheet
Executive SummaryAlmost half (42%) of allergy-sufferers surveyed intend to purchase Schering-Plough's Claritin (loratadine) when it is available OTC, according to study by market research firm Ipsos PharmTrends. Results indicate Claritin "would displace all other OTC and Rx drugs as the preferred remedy," since current OTC category leader, Pfizer Consumer Healthcare's Benadryl, was used by about 32% of allergy sufferers interviewed. Ipsos predicts S-P's successful DTC brand awareness campaign will "carry into the OTC arena, placing incremental pressure" on competing drugs; firm found 91% of allergy sufferers have heard of Claritin. Survey involved random sample of 1,000 adults nationwide...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.